VAX-31
AssetAlso OPUS-1
31-valent pneumococcal conjugate vaccine conferring protection against Streptococcus pneumoniae serotypes
- Stage
- Phase 3
- Modality
- Vaccine
- Target
- Inflammation
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3Invasive pneumococcal disease
Phase 3, globenewswire.com, 4 Oct 2026
Pneumococcal disease
Phase 3, globenewswire.com, 5 Oct 2026
Pneumococcal pneumonia
Phase 3, globenewswire.com, 4 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
Every asset’s record: target, stage, trials and the evidence behind it.